Carolyn Marks
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (1)
Genetic studies have identified hundreds of risk genes for neurodegenerative diseases, yet translating these variants into disease mechanisms remains limited by incomplete knowledge of the protein products. Here, we present the ALS-Reproducible Antibody Platform (ALS-RAP), a systematic effort to characterize 303 antibodies targeting 33 amyotrophic lateral sclerosis (ALS) risk genes: ACSL5, ALS2, ANG, ANXA11, ATXN2, C9orf72, CAV1, CCNF, CHCHD10, CHMP2B, FIG4, FUS, HNRNPA1, HNRNPA2B1, KIF5A, LGALS1, MATR3, NEK1, OPTN, PFN1, SETX, SIGMAR1, SOD1, SPG11, SQSTM1, TAF15, TARDBP, TBK1, TIA1, TUBA4A, UBQLN2, VAPB, and VCP using knockout-based characterization to identify high-quality reagents in common applications. Using these antibodies, we profiled protein expression across human iPSC-derived and primary neurological cell types. Protein-level analyses revealed diverse cell type-specific expression patterns, with subsets of ALS-associated proteins enriched in glial or neuronal populations. This work provides a validated antibody toolbox and ALS protein resource for translating genetic risk into mechanistic insights.
Year:
2025
Collaborators (10)
Thomas M. Durcan
Associate Professor
Montreal Neurological Institute and Hospital
Luke Michael Healy
-
Peter S. McPherson
McGill University
Carl Laflamme
Assistant Professor
University of Ottawa
Opher Gileadi
Head, Protein Sciences
Karolinska Institutet
Edward A. Fon
Professor
Montreal Neurological Institute and Hospital
Guy A Rouleau
Professor
McGill University
Brian D. Marsden
Associate Professor, Research Informatics
University of Oxford
Harvinder Virk
NIHR Academic Clinical Lecturer (Respiratory Medicine)
University of Leicester
Susanne Graslund
Karolinska Institutet
Make your next move.
Prepare your application
Review drafts before you send them.